Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A; TOUCHSTONE Study Group. Sandborn WJ, et al. Among authors: cravets m. N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248. N Engl J Med. 2016. PMID: 27144850 Free article. Clinical Trial.
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW; RADIANCE Study Group. Cohen JA, et al. Among authors: cravets m. Lancet Neurol. 2016 Apr;15(4):373-81. doi: 10.1016/S1474-4422(16)00018-1. Epub 2016 Feb 12. Lancet Neurol. 2016. PMID: 26879276 Clinical Trial.
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
Frantz RP, McLaughlin VV, Sahay S, Escribano Subías P, Zolty RL, Benza RL, Channick RN, Chin KM, Hemnes AR, Howard LS, Sitbon O, Vachiéry JL, Zamanian RT, Cravets M, Roscigno RF, Mottola D, Osterhout R, Bruey JM, Elman E, Tompkins CA, Parsley E, Aranda R, Zisman LS, Ghofrani HA; TORREY Study Investigators. Frantz RP, et al. Among authors: cravets m. Lancet Respir Med. 2024 May 2:S2213-2600(24)00072-9. doi: 10.1016/S2213-2600(24)00072-9. Online ahead of print. Lancet Respir Med. 2024. PMID: 38705167
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets MW, Shaw T. Keystone E, et al. Among authors: cravets mw. Ann Rheum Dis. 2009 Feb;68(2):216-21. doi: 10.1136/ard.2007.085787. Epub 2008 Apr 3. Ann Rheum Dis. 2009. PMID: 18388156 Clinical Trial.
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S. Becker MA, et al. Among authors: cravets m. Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi: 10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21. Semin Arthritis Rheum. 2015. PMID: 26190562 Free article. Clinical Trial.
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Keystone E, et al. Among authors: cravets mw. Arthritis Rheum. 2007 Dec;56(12):3896-908. doi: 10.1002/art.23059. Arthritis Rheum. 2007. PMID: 18050221 Free article. Clinical Trial.
HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Ottoboni T, Lauw M, Keller MR, Cravets M, Manhard K, Clendeninn N, Quart B. Ottoboni T, et al. Among authors: cravets m. Future Oncol. 2019 Mar;15(8):865-874. doi: 10.2217/fon-2018-0809. Epub 2018 Dec 21. Future Oncol. 2019. PMID: 30574797 Free article. Clinical Trial.
14 results